97 related articles for article (PubMed ID: 16268475)
1. Effect of nitroxyl on human platelets function.
Bermejo E; Sáenz DA; Alberto F; Rosenstein RE; Bari SE; Lazzari MA
Thromb Haemost; 2005 Sep; 94(3):578-84. PubMed ID: 16268475
[TBL] [Abstract][Full Text] [Related]
2. Effect of nitroxyl on the hamster retinal nitridergic pathway.
Sáenz DA; Bari SE; Salido E; Chianelli M; Rosenstein RE
Neurochem Int; 2007; 51(6-7):424-32. PubMed ID: 17543420
[TBL] [Abstract][Full Text] [Related]
3. The nitric oxide redox sibling nitroxyl partially circumvents impairment of platelet nitric oxide responsiveness.
Dautov RF; Ngo DT; Licari G; Liu S; Sverdlov AL; Ritchie RH; Kemp-Harper BK; Horowitz JD; Chirkov YY
Nitric Oxide; 2013 Nov; 35():72-8. PubMed ID: 24012721
[TBL] [Abstract][Full Text] [Related]
4. In vitro inhibition of human and rat platelets by NO donors, nitrosoglutathione, sodium nitroprusside and SIN-1, through activation of cGMP-independent pathways.
Priora R; Margaritis A; Frosali S; Coppo L; Summa D; Di Giuseppe D; Aldinucci C; Pessina G; Di Stefano A; Di Simplicio P
Pharmacol Res; 2011 Sep; 64(3):289-97. PubMed ID: 21539916
[TBL] [Abstract][Full Text] [Related]
5. Nitridergic platelet pathway activation by hementerin, a metalloprotease from the leech Haementeria depressa.
Chudzinski-Tavassi AM; Bermej E; Rosenstein RE; Faria F; Sarmiento MI; Alberto F; Sampaio MU; Lazzari MA
Biol Chem; 2003 Sep; 384(9):1333-9. PubMed ID: 14515997
[TBL] [Abstract][Full Text] [Related]
6. Nitroxyl anion donor, Angeli's salt, does not develop tolerance in rat isolated aortae.
Irvine JC; Favaloro JL; Widdop RE; Kemp-Harper BK
Hypertension; 2007 Apr; 49(4):885-92. PubMed ID: 17309955
[TBL] [Abstract][Full Text] [Related]
7. Biological action of nitric oxide donor compounds on platelets from patients with sickle cell disease.
Mondoro TH; Ryan BB; Hrinczenko BW; Schechter AN; Vostal JG; Alayash AI
Br J Haematol; 2001 Mar; 112(4):1048-54. PubMed ID: 11298605
[TBL] [Abstract][Full Text] [Related]
8. Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione.
Gordge MP; Hothersall JS; Noronha-Dutra AA
Br J Pharmacol; 1998 May; 124(1):141-8. PubMed ID: 9630353
[TBL] [Abstract][Full Text] [Related]
9. Differential actions of L-cysteine on responses to nitric oxide, nitroxyl anions and EDRF in the rat aorta.
Ellis A; Li CG; Rand MJ
Br J Pharmacol; 2000 Jan; 129(2):315-22. PubMed ID: 10694238
[TBL] [Abstract][Full Text] [Related]
10. Nitric oxide and platelet energy metabolism.
Tomasiak M; Stelmach H; Rusak T; Wysocka J
Acta Biochim Pol; 2004; 51(3):789-803. PubMed ID: 15448739
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of 1-nitrosocyclohexyl acetate, a long-acting nitroxyl donor that shows vasorelaxant and antiaggregatory effects.
Donzelli S; Fischer G; King BS; Niemann C; DuMond JF; Heeren J; Wieboldt H; Baldus S; Gerloff C; Eschenhagen T; Carrier L; Böger RH; Espey MG
J Pharmacol Exp Ther; 2013 Feb; 344(2):339-47. PubMed ID: 23211362
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation.
Mellion BT; Ignarro LJ; Myers CB; Ohlstein EH; Ballot BA; Hyman AL; Kadowitz PJ
Mol Pharmacol; 1983 May; 23(3):653-64. PubMed ID: 6135148
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide released from activated platelets inhibits platelet recruitment.
Freedman JE; Loscalzo J; Barnard MR; Alpert C; Keaney JF; Michelson AD
J Clin Invest; 1997 Jul; 100(2):350-6. PubMed ID: 9218511
[TBL] [Abstract][Full Text] [Related]
14. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
[TBL] [Abstract][Full Text] [Related]
15. Surface expression of major membrane glycoproteins on resting and TRAP-activated neonatal platelets.
Simák J; Holada K; Janota J; Stranák Z
Pediatr Res; 1999 Oct; 46(4):445-9. PubMed ID: 10509366
[TBL] [Abstract][Full Text] [Related]
16. Nitrovasodilators and cGMP inhibit human platelet activation.
Doni MG; Alexandre A; Padoin E; Bertoncello S; Deana R
Cardioscience; 1991 Sep; 2(3):161-5. PubMed ID: 1660321
[TBL] [Abstract][Full Text] [Related]
17. Calreticulin Transacetylase mediated activation of human platelet nitric oxide synthase by acetyl group donor compounds.
Kumar A; Sushama A; Manral S; Sinha R; Joshi R; Singh U; Rohil V; Prasad AK; Parmar VS; Raj HG
Nitric Oxide; 2012 Jan; 26(1):9-19. PubMed ID: 22100620
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotective actions of nitroxyl donor Angeli's salt are preserved in the diabetic heart and vasculature in the face of nitric oxide resistance.
Velagic A; Li JC; Qin CX; Li M; Deo M; Marshall SA; Anderson D; Woodman OL; Horowitz JD; Kemp-Harper BK; Ritchie RH
Br J Pharmacol; 2022 Aug; 179(16):4117-4135. PubMed ID: 35365882
[TBL] [Abstract][Full Text] [Related]
19. Cathepsin B is a differentiation-resistant target for nitroxyl (HNO) in THP-1 monocyte/macrophages.
Väänänen AJ; Salmenperä P; Hukkanen M; Rauhala P; Kankuri E
Free Radic Biol Med; 2006 Jul; 41(1):120-31. PubMed ID: 16781460
[TBL] [Abstract][Full Text] [Related]
20. The HNO donor Angeli's salt offers potential haemodynamic advantages over NO or dobutamine in ischaemia-reperfusion injury in the rat heart ex vivo.
Chin KY; Michel L; Qin CX; Cao N; Woodman OL; Ritchie RH
Pharmacol Res; 2016 Feb; 104():165-75. PubMed ID: 26747404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
